SavedAdd your journal

Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2020 / Cilt: 73 - Sayı: 1

Our Treatment Approach to Hairy Cell Leukemia

Tüylü Hücreli Lösemide Tedavi Yaklaşımımız

Hamdi AKAN
Selami KOÇAK TOPRAK
Erden ATİLLA
Meral BEKSAÇ
Pervin TOPÇUOĞLU
Muhit ÖZCAN
Pınar ATACA ATİLLA
Günhan GÜRMAN
Osman İLHAN
Ekin KIRCALI
Taner DEMİRER
Önder ARSLAN
Pages
5–8
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Ki-square test and student t-test were used in comparison.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hairy cell leukemia (HCL) is a rare chronic lymphoid malignancy which develops from mature B cells.
📊
Key Findings & Data:The frequency is 2% of all leukemias and diagnosed mostly in middle ages.
💡
Conclusion & Impact:Ki-square test and student t-test were used in comparison.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Hairy cell leukemia (HCL) is a rare chronic lymphoid malignancy which develops from mature B cells. The frequency is 2% of all leukemias and diagnosed mostly in middle ages. Patients respond to treatment with purine analogues. In this study, our aim is to present our HCL patients, their demographic features, treatment modalities and response to therapy. Materials and Methods: Thirty-eight HCL patients who were diagnosed and treated at our center between 1984 and 2019 were retrospectively evaluated. Ki-square test and student t-test were used in comparison. P

Özet

Amaç: Tüylü hücreli lösemi (THL), olgun B hücrelerinden kaynaklanan, nadir görülen bir kronik lenfoid malignitedir. Tüm lösemiler içindeki sıklığı %2olup, hastalar çoğunlukla orta yaşlarda tanı almaktadır. Pürin analogları hastalık tedavisinde kullanılır. Bu çalışmada amacımız THL hastalarımızındemografik özelliklerini, aldıkları tedavileri ve tedaviye cevaplarını sunmaktır.Gereç ve Yöntem: 1984-2019 yılları arasında merkezimizde teşhis ve tedavi edilen 38 THL hastası geriye dönük olarak incelenmiştir. Karşılaştırmalardaki-kare testi ve student t testi kullanılmıştır. P

🔖

Cite This Article

AKAN, H., TOPRAK, S. K., ATİLLA, E., BEKSAÇ, M., TOPÇUOĞLU, P., ÖZCAN, M., ATİLLA, P. A., GÜRMAN, G., İLHAN, O., KIRCALI, E., DEMİRER, T., ARSLAN, Ö. (2022). Our Treatment Approach to Hairy Cell Leukemia. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 73 - Sayı: 1, 5–8. https://ajindex.com/articles/443551

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Shao H, Calvo KR, Grönborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. Leuk Res 2013;37:401-409
  2. Zakarija A, Peterson LC, Tallman MS. Hairy Cell Leukemia. In: Hoffman R, editor. Hematology, Basic Principles and Practice. Churchill-Livingstone- Elsevier; 2009
  3. Frassoldati A, Lamparelli T, Federico M, et al. Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma 1994;13:307- 316
  4. Kraut E. Infectious complications in hairy cell leukemia. Leuk Lymphoma. 2011;52(Suppl 2):50-52
  5. Foucar K, Falini B, Catovsky D, et al. Hairy cell leukaemia. World Healthn Organization Classification of Tumors of Haematopoietics and Lymphoid Tissues. In: Swerdlow SH, Campo E, Harris NL, et al editors. IARC Press, Lyon; 2008. p. 180-190
  6. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017;129:553-560
  7. Rai K. Consensus resolution: Proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia. 1987;1:405
  8. Piris MA, Foucar K, Mollejo M, et al. Splenic B-cell lymphoma/leukaemia, unclassifiable. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: IARC; 2008. p. 191-193
  9. Pettirossi V, Santi A, Imperi E, et al. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood. 2015;125:1207-1216
  10. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012;36:1796-1800
  11. Cannon T, Mobarek D, Wegge J, et al. Hairy cell leukemia: current concepts. Cancer Invest. 2008;26:860-865
  12. Cornet E, Delmer A, Feugier P, et al. French Society of Haematology. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. Ann Hematol. 2014;93:1977-1983
  13. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients withhairy cell leukemia. Blood. 1994;83:2906-2911
  14. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine